Xerosis and pruritus as major EGFRI-associated adverse events.

about

Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors Targeted Therapy-induced Facial Skin Toxicities: Impact on Quality of Life in Cancer Patients.

P2860

Q37496672-B636582B-5715-4BCD-ABC9-E9FD19DA27F0 Q54989077-5B3C9F7B-3C8A-426B-B827-C20CC2A0539E

P2860

Xerosis and pruritus as major EGFRI-associated adverse events.

Item

http://www.wikidata.org/entity/Q36400206

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Xerosis and pruritus as major EGFRI-associated adverse events.

@ast

Xerosis and pruritus as major EGFRI-associated adverse events.

@en

type

Item

label

Xerosis and pruritus as major EGFRI-associated adverse events.

@ast

Xerosis and pruritus as major EGFRI-associated adverse events.

@en

prefLabel

Xerosis and pruritus as major EGFRI-associated adverse events.

@ast

Xerosis and pruritus as major EGFRI-associated adverse events.

@en

P1476

Xerosis and pruritus as major EGFRI-associated adverse events

@en

P2093

Adrian A Kaptein

http://www.w3.org/2001/XMLSchema#string

Christine B Boers-Doets

http://www.w3.org/2001/XMLSchema#string

Hans Gelderblom

http://www.w3.org/2001/XMLSchema#string

Julia M K Clabbers

http://www.w3.org/2001/XMLSchema#string

Koos J M van der Hoeven

http://www.w3.org/2001/XMLSchema#string

Theo Stijnen

http://www.w3.org/2001/XMLSchema#string

P2860

Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.

Skin care management in cancer patients: an evaluation of quality of life and tolerability.

Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.

Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management.

Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors.

Psychosocial impact of cutaneous toxicities associated with epidermal growth factor receptor-inhibitor treatment.

The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18).

Translation and linguistic validation of the FACT-EGFRI-18 quality of life instrument from English into Dutch.

Evaluating the clinical significance of responses by psychiatric inpatients to the mental health subscales of the SF-36.

P2888

s00520-015-2781-y

P304

513-521

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00520-015-2781-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mario E Lacouture

P577

2015-06-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281826013

http://www.w3.org/2001/XMLSchema#string

P698

26111953

http://www.w3.org/2001/XMLSchema#string

P932

4689742

http://www.w3.org/2001/XMLSchema#string

Xerosis and pruritus as major EGFRI-associated adverse events.

about

P2860

P2860

Xerosis and pruritus as major EGFRI-associated adverse events.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932